Compare AXTI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXTI | EVO |
|---|---|---|
| Founded | 1986 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1998 | N/A |
| Metric | AXTI | EVO |
|---|---|---|
| Price | $32.54 | $3.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $24.50 | $7.00 |
| AVG Volume (30 Days) | ★ 6.9M | 133.2K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $99,361,000.00 | N/A |
| Revenue This Year | $44.70 | N/A |
| Revenue Next Year | $42.23 | $7.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 31.09 | N/A |
| 52 Week Low | $1.13 | $2.84 |
| 52 Week High | $47.00 | $4.80 |
| Indicator | AXTI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.36 | 37.40 |
| Support Level | $2.56 | $2.87 |
| Resistance Level | N/A | $3.78 |
| Average True Range (ATR) | 4.95 | 0.09 |
| MACD | 0.23 | -0.05 |
| Stochastic Oscillator | 42.77 | 14.29 |
AXT Inc is a developer and producer of compound and single element semiconductor substrates, also known as wafers. The dominant substrates used in producing semiconductor chips and other electronic circuits are made from silicon. It is engaged in the design, development, manufacture, and distribution of high-performance compound semiconductor substrates and the sale of materials. The company provides alternative or specialty materials in the form of substrates or wafers, including compound and single-element substrates. Its compound substrates combine indium with phosphorous or gallium with arsenic. Geographically firm has its business presence across the region of Europe, Japan, Taiwan, China, North America, and the Asia Pacific from which China derives its maximum revenue to the company.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.